Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Biotech
Genmab discards ADC from $1.8B ProfoundBio buy
The discarded candidate, dubbed GEN1107, is a PTK7-targeted ADC that was being studied in a phase 1/2 solid tumor trial.
Gabrielle Masson
Sep 16, 2025 10:33am
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
Sep 8, 2025 11:00am
Daiichi, Merck rev up for accelerated approval filing
Sep 7, 2025 10:45am
China-based Novatim notches new deal with another US biotech
Sep 2, 2025 2:36pm
CytomX reports patient death from kidney injury in ADC trial
Aug 14, 2025 6:45am
Ipsen hands back Sutro's ROR1 ADC at center of $875M deal
Aug 8, 2025 6:15am
